In the last trading session, 2.27 million UroGen Pharma Ltd (NASDAQ:URGN) shares changed hands as the company’s beta touched 0.82. With the company’s per share price at $13.49 changed hands at $0.38 or 2.90% during last session, the market valuation stood at $621.99M. URGN’s last price was a discount, traded about -34.54% off its 52-week high of $18.15. The share price had its 52-week low at $3.42, which suggests the last value was 74.65% up since then. When we look at UroGen Pharma Ltd’s average trading volume, we note the 10-day average is 5.11 million shares, with the 3-month average coming to 2.80 million.
Analysts gave the UroGen Pharma Ltd (URGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended URGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
UroGen Pharma Ltd (NASDAQ:URGN) trade information
Instantly URGN was in green as seen at the end of in last trading. With action -7.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -18.19%, with the 5-day performance at -7.92% in the red. However, in the 30-day time frame, UroGen Pharma Ltd (NASDAQ:URGN) is 233.09% up. Looking at the short shares, we see there were 6.13 million shares sold at short interest cover period of 1.11 days.
The consensus price target for the stock as assigned by Wall Street analysts is 23.5, meaning bulls need an upside of 42.6% from its current market value. According to analyst projections, URGN’s forecast low is 16 with 31 as the target high. To hit the forecast high, the stock’s price needs a -129.8% plunge from its current level, while the stock would need to soar -18.61% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.39%. The 2025 estimates are for UroGen Pharma Ltd earnings to increase by 1.54%.
URGN Dividends
UroGen Pharma Ltd is expected to release its next quarterly earnings report on 2025-May-12.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.87% of UroGen Pharma Ltd shares while 105.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 113.10%. There are 105.33% institutions holding the UroGen Pharma Ltd stock share, with RTW INVESTMENTS, LP the top institutional holder. As of 2024-06-30, the company held 9.661% of the shares, roughly 3.56 million URGN shares worth $59.69 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 8.9621% or 3.3 million shares worth $55.37 million as of 2024-06-30.
